Drug Trial Radar · NCT05607641
Efficacy and Safety Study of Ketorolac / Pitofenone / Fenpiverinium for the Treatment of Patients With Pain After Surgical Abdominal and Pelvic Operations
Last checked: Nov 20, 2026Latest source record: Nov 7, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
424
Actual
Start
Jul 7, 2021
Primary completion
May 7, 2022
Study completion May 13, 2022
Sponsor
- Lead sponsor
- Darnitsa Pharmaceutical CompanyIndustry
- Sponsor type
- Industry
- First posted
- Nov 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Neospastil (ketorolac tromethamine / pitofenone hydrochloride / fenpiverinium bromide fixed-dose combination) in a form of solution for injections and film-coated tablets has been studied as a treatment for pain after surgical abdominal and pelvic operations. The aim of the study was to test the hypothesis that Neospastil was non-inferior (phase II) and superior (phase III) than ketorolac tromethamine monotherapy due to the additional relaxing effect of pitofenone and fenpiverinium on the smooth muscles of internal organs. The study also aimed to show that Neospastil is safe and well-tolerated in people who have pain after surgical abdominal and pelvic operations. Study treatment was initiated with parenteral form of study drug (first 24 hours) and then switched to oral formulation. This trial was conducted in accordance with the ethical principles of Good Clinical Practice and International Council for Harmonization (ICH) Harmonized Tripartite Guidelines.
Conditions
- Postsurgical Pain
Interventions
Ketorolac tromethamine, solution for injection then Neospastil, film-coated tabletsDrug
These medicines were used for patients of Group 1 (phase II) and Group 4 (phase III). Stage 1 (1st day of study treatment) - Ketorolac tromethamine, solution for injection, 1 ml every 8 hours. Stage 2 (2nd day of study treatment) - Neospastil, film-coated tablets, 1 tablet every 6 hours. Stage 3 (3rd-5th days of study treatment) - Neospastil, film-coated tablets, 1 tablet on demand with an interval of at least 6 hours, not more than 4 tablets per day.
Ketorolac tromethamine, solution for injection then Ketorolac tromethamine, coated tabletsDrug
These medicines were used for patients of Group 2 (phase II) and Group 5 (phase III). Stage 1 (1st day of study treatment) - Ketorolac tromethamine, solution for injection, 1 ml every 8 hours. Stage 2 (2nd day of study treatment) - Ketorolac tromethamine, coated tablets, 1 tablet every 6 hours. Stage 3 (3rd-5th days of study treatment) - Ketorolac tromethamine, coated tablets, 1 tablet on demand with an interval of at least 6 hours, not more than 4 tablets per day.
Neospastil, solution for injection then Neospastil, film-coated tabletsDrug
These medicines were used for patients of Group 3 (phase II) and Group 6 (phase III). Stage 1 (1st day of study treatment) - Neospastil, solution for injection, 2 ml every 8 hours. Stage 2 (2nd day of study treatment) - Neospastil, film-coated tablets, 1 tablet every 6 hours. Stage 3 (3rd-5th days of study treatment) - Neospastil, film-coated tablets, on demand 1 tablet with an interval of at least 6 hours, not more than 4 tablets per day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of study subjects who achieved a response to treatment within the first 24 hours of using IMP in the form of solution for injections.Time frame: Stage 1 (1st day of treatment).
- Proportion of study subjects who achieved a response to treatment within the first 24 hours of using IMP in the form of tablets.Time frame: Stage 2 (2nd day of treatment).
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Regional municipal nonprofitable institution "Chernivtsi regional clinical hospital", urological department
Chernivtsi, Ukraine
Communal enterprise "Dnipropetrovsk Regional Clinical Hospital named after І.І. Mechnikov" Dnipropetrovsk Regional Council", urology department №1
Dnipro, Ukraine
Communal enterprise "Dnipropetrovsk Regional Clinical Hospital named after І.І. Mechnikov" Dnipropetrovsk Regional Council", urology department №2
Dnipro, Ukraine
Communal noncomercial enterprise of the Kharkiv Regional Council "Regional Medical Clinical Center of Urology and Nephrology named after V.I. Shapovala", urology department №5
Kharkiv, Ukraine
Communal noncomercial enterprise "Kyiv City Clinical Hospital #3" Kyiv City Council (Kyiv City State Administration), urological department
Kyiv, Ukraine
Medical Center of the LLC "Harmony of Beauty"
Kyiv, Ukraine
State Institution "Institute of Urology of the National Academy of Medical Sciences of Ukraine", I Urological Department
Kyiv, Ukraine
Communal noncomercial enterprise of the Lviv Regional Council "Lviv Regional Clinical Hospital", department of urology
Lviv, Ukraine
Municipal Non-profit Enterprise "Lviv Clinical Hospital for Emergency Medical Care"
Lviv, Ukraine
Communal noncomercial enterprise "City Clinical Hospital #10" Odesa City Council, urological department #2
Odesa, Ukraine
Medical-diagnostic center" Zakarpattya center of surgical innovations" Astra-med "of limited liability company" Clinic of healthy family "Astramed"
Uzhhorod, Ukraine
Communal noncomercial enterprise" Vinnytsia City Clinical Hospital" Mother and Child Center", department of gynecology with minimally invasive operations
Vinnytsia, Ukraine
Limited Liability Company "Innomed Center of Endosurgery"
Vinnytsia, Ukraine
Communal noncomercial enterprise "City Hospital of Emergency and Ambulance" of Zaporizhia City Council, Department of Surgery with the Center for Gastrointestinal Bleeding
Zaporizhzhya, Ukraine
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.